Bayer AG has proposed a $7.25 billion settlement to resolve thousands of pending U.S. lawsuits alleging that its Roundup herbicide causes cancer. The settlement will be funded through capped annual payments distributed over a period of up to 21 years, providing the company with predictable cash outflows while offering claimants a defined resolution pathway.
The proposed settlement addresses significant litigation exposure facing the pharmaceutical and agrochemicals conglomerate following its 2018 acquisition of Monsanto, the herbicide's manufacturer. The settlement framework comes as the U.S. Supreme Court prepares to hear oral arguments on a case that could fundamentally alter the legal landscape by determining whether federal EPA approval of Roundup preempts state-level cancer injury claims.
By advancing this settlement proposal, Bayer aims to resolve accumulated litigation risk and reduce uncertainty surrounding potential adverse rulings from the Supreme Court. The structured payment arrangement allows the company to manage financial obligations while providing clarity to plaintiffs regarding compensation outcomes, potentially avoiding prolonged legal proceedings and unpredictable damage awards.